Furthermore, the increase of apo E-containing HDL particles in the CETPi arm of the dal-PLAQUE-2 clinical trial suggests that statins do not prevent the effect of dalcetrapib on apo E in patients with CAD. Here, APOE is linked to coronary artery disorder.